Samuel D Isaly
CIK 1055949 · last filed 2018-01-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LOXO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
54TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 68,759 | $13.60 | $935.1K | -$40.22M | 2 | 2018-01-04 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 1,191,000 | — | — | -$109.49M | 3 | 2017-11-27 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | 10%+ Owner | 33 | $0.08 | $3 | $0 | 1 | 2017-11-20 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 0 | — | — | -$1.44M | 2 | 2017-10-05 |
| BOLD | 10%+ Owner | 4,806,638 | $2.41 | $11.58M | -$335.2K | 1 | 2017-09-11 |
| GKOS | Director | 1,628,111 | $181.17 | $294.96M | -$89.00M | 2 | 2017-08-17 |
| KALA | 10%+ Owner | 951 | $0.18 | $167 | $14.37M | 1 | 2017-07-27 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 3,298,516 | $64.97 | $214.30M | $0 | 1 | 2017-07-26 |
| ASND | Director | 6,149,377 | $245.85 | $1.51B | $15.00M | 1 | 2017-03-28 |
| CRVS | Director | 5,379,349 | $10.54 | $56.70M | $464.3K | 3 | 2016-06-27 |
| OTONOMY, INC. (OTIC) Delisted | Director | 1,953,300 | $0.08 | $150.4K | -$17.21M | 1 | 2015-11-24 |
| Sientra, Inc. (SIEN) Delisted | 10%+ Owner | 1,988 | $0.17 | $346 | -$14.36M | 1 | 2015-10-09 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,725,790 | — | — | $8.93M | 1 | 2015-07-21 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 1,656,582 | $19.00 | $31.48M | $0 | 2 | 2014-08-11 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 27,531 | — | — | $2.30M | 2 | 2013-01-29 |
| SUPN | 10%+ Owner | 0 | $40.96 | $0 | -$6.19M | 1 | 2012-12-19 |
| GNOM | 10%+ Owner | 730,535 | $68.80 | $50.26M | -$9.91M | 1 | 2012-07-13 |
| PCRX | 10%+ Owner | 2,546,100 | $36.40 | $92.68M | -$1.40M | 1 | 2012-02-29 |
| CCXI | 10%+ Owner | 908,509 | $10.24 | $9.30M | $0 | 1 | 2012-02-15 |
| AMRN | Director | 345,455 | $11.95 | $4.13M | -$1.72M | 1 | 2011-03-07 |
| NxStage Medical, Inc. (NXTM) Delisted | Director | 4,152,700 | — | — | -$1.67M | 2 | 2010-09-09 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | 50,430 | — | — | -$282.8K | 1 | 2009-06-11 |
| ATHERSYS, INC / NEW (ATHX) Delisted | Director | 137,920 | $0.01 | $1.9K | $1.91M | 2 | 2008-05-23 |
Recent Filings · Page 2 of 4
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-07-26 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | +9,895,548 | $0 | EDGAR |
| 2017-03-28 | ASND | Buy (P) | +3,571,428 | $15.00M | EDGAR |
| 2017-03-17 | — | Buy (P) | +2,288,985 | $11.44M | |
| 2017-03-14 | GKOS | Sell (S) | −1,147,614 | -$52.02M | EDGAR |
| 2016-06-27 | CRVS | Buy (P) | +3,000 | $38.9K | EDGAR |
| 2016-05-24 | CRVS | Buy (P) | +14,148 | $185.2K | EDGAR |
| 2016-05-20 | CRVS | Buy (P) | +20,400 | $240.1K | EDGAR |
| 2015-11-24 | OTONOMY, INC. (OTIC) Delisted | Sell (S) | −602,400 | -$17.21M | EDGAR |
| 2015-10-09 | Sientra, Inc. (SIEN) Delisted | Sell (S) | −1,999,827 | -$14.36M | EDGAR |
| 2015-07-21 | Sierra Oncology, Inc. (DNAI) Delisted | Mixed | +5,969,847 | $10.32M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.